Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M. Novelli F, et al. Among authors: fabi a. Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4. Breast Cancer Res. 2008. PMID: 18771580 Free PMC article.
Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Nisticò C, Garufi C, Milella M, D'Ottavio AM, Vaccaro A, Fabi A, Terzoli E. Nisticò C, et al. Among authors: fabi a. Breast Cancer Res Treat. 1999 Aug;56(3):233-7. doi: 10.1023/a:1006213815195. Breast Cancer Res Treat. 1999. PMID: 10573114 Clinical Trial.
Weekly schedule of vinorelbine in pretreated breast cancer patients.
Nisticò C, Garufi C, Milella M, Vaccaro A, D'Ottavio AM, Fabi A, Pace A, Bove L, Tropea F, Marsella A, Izzo F, D'Attino RM, Ferraresi V, De Marco S, Terzoli E. Nisticò C, et al. Among authors: fabi a. Breast Cancer Res Treat. 2000 Feb;59(3):223-9. doi: 10.1023/a:1006390700480. Breast Cancer Res Treat. 2000. PMID: 10832592 Clinical Trial.
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Papaldo P, et al. Among authors: fabi a. J Clin Oncol. 2003 Sep 15;21(18):3462-8. doi: 10.1200/JCO.2003.03.034. J Clin Oncol. 2003. PMID: 12972521 Clinical Trial.
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.
Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F. Di Cosimo S, et al. Among authors: fabi a. Ann Oncol. 2004 Jul;15(7):1065-71. doi: 10.1093/annonc/mdh266. Ann Oncol. 2004. PMID: 15205200 Free article.
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, Fabi A, Nisticò C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Terzoli E, Cognetti F. Carlini P, et al. Among authors: fabi a. Cancer. 2005 Oct 1;104(7):1335-42. doi: 10.1002/cncr.21339. Cancer. 2005. PMID: 16088965 Free article. Review.
324 results